BR9907256A - Inibidores beta-cetoamida de proteassoma 20s - Google Patents

Inibidores beta-cetoamida de proteassoma 20s

Info

Publication number
BR9907256A
BR9907256A BR9907256-4A BR9907256A BR9907256A BR 9907256 A BR9907256 A BR 9907256A BR 9907256 A BR9907256 A BR 9907256A BR 9907256 A BR9907256 A BR 9907256A
Authority
BR
Brazil
Prior art keywords
proteasome
beta
ketoamide
inhibitors
ketoamide inhibitors
Prior art date
Application number
BR9907256-4A
Other languages
English (en)
Inventor
Lisa Wang
Robert T Lum
Steven R Schow
Alison Joly
Suresh Kerwar
Michael M Wick
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of BR9907256A publication Critical patent/BR9907256A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<B>INIBIDORES <244>-CETOAMIDA DE PROTEASSOMA 20S<D> Compostos de <244>-cetoamida úteis para o tratamento de distúrbios mediados por proteassoma 20S em mamíferos, tendo a seguinte estrutura (I).
BR9907256-4A 1998-01-26 1999-01-19 Inibidores beta-cetoamida de proteassoma 20s BR9907256A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/013,365 US6075150A (en) 1998-01-26 1998-01-26 α-ketoamide inhibitors of 20S proteasome
PCT/US1999/001097 WO1999037666A1 (en) 1998-01-26 1999-01-19 α-KETOAMIDE INHIBITORS OF 20S PROTEASOME

Publications (1)

Publication Number Publication Date
BR9907256A true BR9907256A (pt) 2001-10-09

Family

ID=21759598

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907256-4A BR9907256A (pt) 1998-01-26 1999-01-19 Inibidores beta-cetoamida de proteassoma 20s

Country Status (20)

Country Link
US (2) US6075150A (pt)
EP (1) EP1058689A1 (pt)
JP (1) JP3863370B2 (pt)
KR (1) KR100417888B1 (pt)
CN (1) CN1289340A (pt)
AR (1) AR012781A1 (pt)
AU (1) AU747835B2 (pt)
BR (1) BR9907256A (pt)
CA (1) CA2319150C (pt)
GE (1) GEP20032869B (pt)
HU (1) HUP0100901A3 (pt)
IL (2) IL137475A0 (pt)
NO (1) NO327049B1 (pt)
NZ (1) NZ505892A (pt)
PL (1) PL202504B1 (pt)
RU (1) RU2192429C2 (pt)
TW (1) TW593339B (pt)
UA (1) UA71559C2 (pt)
WO (1) WO1999037666A1 (pt)
ZA (1) ZA99161B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US6949567B2 (en) 2001-02-26 2005-09-27 4Sc Ag Compounds for the treatment of protozoal diseases
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
JP2005535574A (ja) 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
BRPI0510802A (pt) * 2004-05-10 2007-11-06 Proteolix Inc compostos para inibição de enzima
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20070027067A1 (en) * 2005-05-13 2007-02-01 Felicia Etzkorn Transition-state Inhibitors of Pin1, alpha-Ketoamide-containing peptidomimetics, and synthesis thereof
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
TWI412535B (zh) 2005-07-29 2013-10-21 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑（五）
ES2373685T3 (es) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
JP5436860B2 (ja) * 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
US8594771B2 (en) * 2005-12-28 2013-11-26 General Electric Company Devices and methods for self-administered ECG examinations
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
PT2120991E (pt) * 2007-02-12 2014-05-02 Biotempt Bv Tratamento d a hemorragia traumática com oligopéptidos curtos
US8859021B2 (en) * 2007-05-14 2014-10-14 Sytheon Skin appearance through gene manipulation
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
HRP20150592T4 (hr) 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
PH12012501719A1 (en) 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
US8697646B2 (en) 2010-04-07 2014-04-15 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
PL2742356T3 (pl) 2011-08-11 2016-11-30 Środki prognostyczne w leczeniu nowotworów
CA2862580A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
CA2855368A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
JP6486826B2 (ja) 2012-10-01 2019-03-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
EP2906581A1 (en) * 2012-10-11 2015-08-19 F. Hoffmann-La Roche AG Ketoamide immunoproteasome inhibitors
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
SG10202003693RA (en) 2014-05-20 2020-05-28 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
JP6859559B2 (ja) * 2017-03-16 2021-04-14 二村　芳弘 抗アレルギー作用を呈するフェニルペプチド誘導体
JP7219473B2 (ja) * 2017-08-28 2023-02-08 静岡県公立大学法人 コリバクチンおよびコリバクチン産生菌の検出方法および検出プローブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206078B (it) * 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
JPH04211648A (ja) * 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd ケト酸アミド誘導体
US5430022A (en) * 1990-05-14 1995-07-04 Fujisawa Pharmaceutical Co., Ltd. Peptide compound and its preparation
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones

Also Published As

Publication number Publication date
ZA99161B (en) 1999-07-28
CA2319150A1 (en) 1999-07-29
IL137475A0 (en) 2001-07-24
GEP20032869B (en) 2003-01-27
HUP0100901A3 (en) 2001-11-28
NO20003807L (no) 2000-09-25
NO327049B1 (no) 2009-04-14
IL137475A (en) 2006-10-05
WO1999037666A1 (en) 1999-07-29
AU2326799A (en) 1999-08-09
RU2192429C2 (ru) 2002-11-10
CN1289340A (zh) 2001-03-28
NZ505892A (en) 2002-10-25
US6781000B1 (en) 2004-08-24
HUP0100901A2 (hu) 2001-08-28
CA2319150C (en) 2004-08-31
TW593339B (en) 2004-06-21
AR012781A1 (es) 2000-11-08
NO20003807D0 (no) 2000-07-25
US6075150A (en) 2000-06-13
JP3863370B2 (ja) 2006-12-27
PL343269A1 (en) 2001-08-13
JP2002501080A (ja) 2002-01-15
UA71559C2 (en) 2004-12-15
AU747835B2 (en) 2002-05-23
KR100417888B1 (ko) 2004-02-11
PL202504B1 (pl) 2009-06-30
EP1058689A1 (en) 2000-12-13
KR20010034381A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
CA2319150A1 (en) .alpha.-ketoamide inhibitors of 20s proteasome
DE69933257D1 (de) Lithographische Vorrichtung
NO20030503D0 (no) Bearbeidingsinstrument for pröveinnretninger
DE69931893D1 (de) Setzwerkzeug für knochenanker
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
BR9906888A (pt) &#34;travessa&#34;
DE69902077D1 (de) Vorrichtung zur Reinigung von Wasserstoff
BR9804676A (pt) Processo para o teste de um dispositivo de embreagem automatizado.
BR9813905A (pt) Instalação para influenciar uma instalação de iluminação
DE19882984T1 (de) Schraubenspindel für Vakuumpumpen
DE69930027D1 (de) Metallisierungsverfahren für Halbleiter
ATE290729T1 (de) Gerätegehalter ,insbesondere für elektrisches gerät und damit ausgerüstetes gehäuse
BR0014626A (pt) Análise de leptina
DE69732302D1 (de) Kompakte vorrichtung für beleuchtung
DE59905657D1 (de) Beleuchtungseinrichtung für ein operationsmikroskop
DE59900396D1 (de) Befestigungsvorrichtung für flächige Bauteile
DE69934576D1 (de) Plattenklem mechanismus für plattengerät
DE59511077D1 (de) Analysegerät, insbesondere für Abwasser
DE69506782D1 (de) Gehäuse, insbesondere für Niederspannungsgeräte
DE69935113D1 (de) Kühlvorrichtung für Supraleiter
DE69940531D1 (de) Vorrichtung für Gleichstrom-Energiespeichereinrichtung
EA200001104A1 (ru) Аскорбат пароксетина
BR9700040A (pt) Máquina copiadora tendo um instrumento para remover grampo ativo
DE69905697T2 (de) Vorrichtung für walzgeräte
NO20012301D0 (no) Ny fremgangsmåte for behandling

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: NA PETICAO NO 003791 DE 21.01.2002 FOI REQUERIDO O EXAME DO PEDIDO DE PATENTE DE INVENCAO PI9907256-4 CONTENDO 28 REIVINDICACOES. VERIFICOU-SE O PAGAMENTO DA TAXA RELATIVA AO PEDIDO DE EXAME DE 28 REIVINDICACOES (FL. 110 DO PROCESSO). NO ENTANTO, O QUADRO REIVINDICATORIO (FLS. 102-106 DO PROCESSO), QUE FOI ALTERADO NA PETICAO NO049611 DE 06.12.2000, POSSUI UM TOTAL DE 29 REIVINDICACOES. A REQUERENTE DEVERA COMPLEMENTAR O VALOR DA TAXA DE EXAME REFERENTE A REIVINDICACAO EXCEDENTE, PARA QUE SE DE PROSSEGUIMENTO AO EXAME TECNICO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 24 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.